table of contents pipeline insight hepatitis c protease inhibitors to drive market expansion critical assessment products in clinical development for chronic hcv with depth analysis and revenue forecast key late stage small molecule antivirals immunomodulators includes epidemiological update unmet need product code dmhc2188 price 11400 publication date 23 jun 2006 overview introduction an estimated 10 million people the seven major markets have current standard care pegylated interferon peg ifn plus ribavirin rbv achieves long term disease remission approximately half those receiving treatment more efficacious therapies are required improve success difficult treat patients particular genotype 1 scope comprehensive compounds including interferons forecasts from 2015 as a whole appraisal trial design highlighting rising complexity associated patient stratification trend towards multidrug therapy expert opinion on drugs their potential use outlook evolution prevailing needs report highlights concomitant new drug launches 2009 onwards
